Merck Announces Update On Bellwave Clinical Development Program Evaluating Nemtabrutinib
Nov 17 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES UPDATE ON BELLWAVE CLINICAL DEVELOPMENT PROGRAM EVALUATING NEMTABRUTINIB
MERCK & CO - DISCONTINUES PHASE 3 BELLWAVE-011 TRIAL (NCT06136559) AFTER EDMC REVIEW
MERCK & CO - DISCONTINUES PHASE 3 BELLWAVE-008 AND BELLWAVE-010 STUDIES
MERCK & CO - DISCONTINUES CLINICAL DEVELOPMENT PROGRAM FOR NEMTABRUTINIB (MK-1026)
MERCK & CO - DATA ANALYSES FOR DISCONTINUED TRIALS ONGOING; RESULTS TO BE SHARED
Further company coverage: MRK.N